These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 10642802

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
    Ferrara F, Palmieri S, Annunziata M, Viola A, Pocali B, Califano C, D'Arco AM, Mele G.
    Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
    [Abstract] [Full Text] [Related]

  • 23. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC, Dekker-Van Roessel HM, Jonkhoff AR, Admiraal GC, Zweegman S, Schuurhuis GJ, Ossenkoppele GJ.
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Intensive chemotherapy with stem cell support-experience in pediatric solid tumours.
    Pinkerton CR.
    Bull Cancer; 1995 May; 82 Suppl 1():61s-65s. PubMed ID: 7626856
    [Abstract] [Full Text] [Related]

  • 26. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Sauer M, Zeidler C, Meissner B, Rehe K, Hanke A, Welte K, Lohse P, Sykora KW.
    Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
    [Abstract] [Full Text] [Related]

  • 27. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, Vassal G.
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [Abstract] [Full Text] [Related]

  • 28. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Celebi H, Ustün C, Akan H, Demirer S, Aydintuğ S, Uysal A, Koç H.
    Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
    [Abstract] [Full Text] [Related]

  • 29. High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma.
    Graham-Pole J, Lazarus HM, Herzig RH, Gross S, Coccia P, Weiner R, Strandjord S.
    Am J Pediatr Hematol Oncol; 1984 Apr; 6(1):17-26. PubMed ID: 6370012
    [Abstract] [Full Text] [Related]

  • 30. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [Abstract] [Full Text] [Related]

  • 31. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
    Palumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V, Grasso M, Liberati M, Lotesoriere C, Marcenò R, Marmont F, Musto P, Petrucci MT, Spriano M, Pileri A, Boccadoro M.
    Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
    [Abstract] [Full Text] [Related]

  • 32. Hemopoietic reconstitution after repeated autologous transplantation with mafosfamide-purged marrow.
    Beaujean F, Hartmann O, Benhamou E, Lemerle J, Duedari N.
    Bone Marrow Transplant; 1989 Sep; 4(5):537-41. PubMed ID: 2790332
    [Abstract] [Full Text] [Related]

  • 33. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 34. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
    Wall DA, Carter SL, Kernan NA, Kapoor N, Kamani NR, Brochstein JA, Frangoul H, Goyal RK, Horan JT, Pietryga D, Wagner JE, Kurtzberg J, COBLT Steering Committee.
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
    [Abstract] [Full Text] [Related]

  • 35. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [Abstract] [Full Text] [Related]

  • 36. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, Somlo G.
    Anticancer Res; 2009 Aug; 29(8):3281-8. PubMed ID: 19661346
    [Abstract] [Full Text] [Related]

  • 37. [Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia].
    Matsuyama T, Kato K, Hanada R, Kawa K, Okamura J, Tsuchida M, Kigasawa H, Watanabe A, Hamamoto K, Kudoh T, Sano K, Ohira M, Hematopoietic Stem Cell Transplantation Study Group of Pediatric ALL.
    Rinsho Ketsueki; 2002 Jul; 43(7):527-37. PubMed ID: 12229121
    [Abstract] [Full Text] [Related]

  • 38. Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study.
    González-Vicent M, Molina B, Pérez A, Díaz MA.
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):180-3. PubMed ID: 22430583
    [Abstract] [Full Text] [Related]

  • 39. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
    Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, Egeler M, Lankester AC, Egberts AC, Zwaveling J, Boelens JJ.
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):231-41. PubMed ID: 19167683
    [Abstract] [Full Text] [Related]

  • 40. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.